title: A case report of a new pulmonary embolism occurring in a patient receiving continuous infusion of recombinant activated protein C.
abstract: BACKGROUND
  There are no guidelines governing the concomitant use of recombinant human activated protein C (rhAPC) and deep venous thrombosis/pulmonary embolism (DVT/PE) prophylaxis in critically ill patients. It is unknown if rhAPC provides any protection against DVT/PE in this population of patients.
  
  
  METHODS
  Case report.
  
  
  RESULTS
  This report describes the first case of a radiographically demonstrated pulmonary embolism occurring in a patient receiving continuous therapeutic infusion of rhAPC.
  
  
  CONCLUSIONS
  The administration of rhAPC alone may not be sufficient DVT/PE prophylaxis in high risk patients. The risks associated with concomitant anticoagulation and rhAPC therapy are unknown. Further research is necessary to determine the safest and most effective regimen for DVT/PE prophylaxis in patients receiving rhAPC.
authors.affiliation: Rhode Island Hospital, Brown University School of Medicine, 2 Dudley Street, Providence, RI, USA.
authors.forename: Bernard J
authors.initials: BJ
authors.lastname: Benedetto
authors.affiliation: University of North Carolina Medical Center, University of North Carolina School of Medicine, Chapel Hill, NC, USA.
authors.forename: Michael A
authors.initials: MA
authors.lastname: Houston